Release Notes for BAO version 2.8.8

Contact: Stephan Schurer (sschurer at med dot miami dot edu)

Release Date:September 8, 2023

### About BAO

The BioAssay Ontology (BAO) has been developed to formally describe biological screening assays and their results including high-throughput screening (HTS) data; specifically in the domain of small molecule drug and probe development. BAO enables categorization of assays and results by based on several concepts that are important to interpret and analyze screening data with the goal to infer the mechanism of action of small molecules based on the known aggregate screening results from many assays.

### Changes in BAO v 2.8.8

**Add BAO classes**

File Module BAO ID BAO label

----------------- ----------- --------------------

vocabulary\_assay BAO\_0013019 clearance

vocabulary\_assay BAO\_0013020 CLint

vocabulary\_format BAO\_0020011 blood format

vocabulary\_result BAO\_0080048 fraction metabolised

**Add external class**

Partition Coefficient (<http://purl.obolibrary.org/obo/NCIT_C20610>)

**Update label**

UGT chemical inhibition | new label : UGT chemical inhibition assay

CYP chemical inhibition | new label : CYP chemical inhibition assay

CYP reaction phenotyping | new label : CYP reaction phenotyping assay

**Add synonym**

S9 fraction format, add synonym : S9 format

**Add axioms**

| **label 1** | **property** | **cardinality** | **label 2** |
| --- | --- | --- | --- |
| blood to plasma ratio assay | has assay format | some | blood format |
| CYP reaction phenotyping | has assay format | some | S9 fraction format |
| S9 stability assay | has assay format | some | S9 fraction format |
| CYP chemical inhibition | has endpoint | some | fraction metabolised |
| CYP metabolite formation kinetics | has endpoint | some | fraction metabolised |
| CYP reaction phenotyping | has endpoint | some | fraction metabolised |
| hepatocyte relay assay | has endpoint | some | fraction metabolised |
| hepatocyte stability assay | has endpoint | some | CLint |
| microsomal stability assay | has endpoint | some | CLint |
| tissue binding assay | has endpoint | some | Partition Coefficient |
| BCRP inhibition assay | has assay design method | some | liquid chromatography |
| BCRP substrate assay | has assay design method | some | liquid chromatography |
| biliary excretion assay | has assay design method | some | liquid chromatography |
| blood to plasma ratio assay | has assay design method | some | liquid chromatography |
| CYP3A4 induction assay | has assay design method | some | liquid chromatography |
| hepatocyte low clearance relay assay | has assay design method | some | liquid chromatography |
| MAO reaction phenotyping assay | has assay design method | some | liquid chromatography |
| mass balance assay | has assay design method | some | liquid chromatography |
| MATE1 inhibition assay | has assay design method | some | liquid chromatography |
| MATE1 substrate assay | has assay design method | some | liquid chromatography |
| metabolite identification and profiling assay | has assay design method | some | liquid chromatography |
| human mammary epithelial cell permeability assay | has assay design method | some | liquid chromatography |
| monoamine oxidase inhibition assay | has assay design method | some | liquid chromatography |
| MRP2 inhibition assay | has assay design method | some | liquid chromatography |
| MRP2 substrate assay | has assay design method | some | liquid chromatography |
| OAT1 inhibition assay | has assay design method | some | liquid chromatography |
| OAT1 substrate assay | has assay design method | some | liquid chromatography |
| OAT2 inhibition assay | has assay design method | some | liquid chromatography |
| OAT2 substrate assay | has assay design method | some | liquid chromatography |
| OAT3 inhibition assay | has assay design method | some | liquid chromatography |
| OAT3 substrate assay | has assay design method | some | liquid chromatography |
| OATP1B1 inhibition assay | has assay design method | some | liquid chromatography |
| OATP1B1 substrate assay | has assay design method | some | liquid chromatography |
| OATP1B3 inhibition assay | has assay design method | some | liquid chromatography |
| OATP1B3 substrate assay | has assay design method | some | liquid chromatography |
| OATP2B1 substrate assay | has assay design method | some | liquid chromatography |
| OCT1 inhibition assay | has assay design method | some | liquid chromatography |
| OCT1 substrate assay | has assay design method | some | liquid chromatography |
| placental transfer assay | has assay design method | some | liquid chromatography |
| renal excretion assay | has assay design method | some | liquid chromatography |
| simulated intestinal fluid stability assay | has assay design method | some | liquid chromatography |

### Github

<https://github.com/BioAssayOntology/BAO/issues/67>

<https://github.com/BioAssayOntology/BAO/issues/99>

<https://github.com/BioAssayOntology/BAO/issues/98>

<https://github.com/BioAssayOntology/BAO/issues/97>

<https://github.com/BioAssayOntology/BAO/issues/100>

### Public Location:

[http://www.bioassayontology.org/bao](http://www.bioassayontology.org/bao/bao_complete.owl)

### License/Disclaimer

This document as well as the Reference and OWL ontology document are released under the [Creative Commons Attribution 4.0 International Public License ("Public License")](https://github.com/BioAssayOntology/BAO/blob/master/LICENSE).